COMBATTING QUINOLONE ANTIMICROBIAL RESISTANCE

对抗喹诺酮类抗菌药物耐药性

• 批准号: 6729491
• 负责人: LYNN ZECHIEDRICH
• 金额: $ 33.86万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-15 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6729491
• 关键词: DNA topoisomerases; Escherichia coli; antiinfective agents; bacterial genetics; bioinformatics; clinical research; drug resistance; functional /structural genomics; gene environment interaction; gene interaction; gene mutation; genome; high throughput technology; human population study; human subject; membrane transport proteins; molecular cloning; multidrug resistance; patient oriented research; quinoline; statistics /biometry

DESCRIPTION (provided by applicant): Quinolones are some of the most frequently used, broad-spectrum antimicrobial agents. Resistance to these drugs has become a critical public health problem. Mutations in the drug target topoisomerases that result in drug resistance are well documented. In addition, overproduction of the multidrug efflux pump AcrAB has been reported to result in quinolone resistance in clinical isolates of E. coli. Our long-range goal is to determine how bacteria respond to exposure to quinolone agents and to use this knowledge to design more effective treatments. A goal of the present proposal is to identify the genetic alterations that lead to quinolone resistance in clinical E. coli strains and to determine the interrelationship between levels and frequency of quinolone resistance, the mutations, and other patient covariates. The central hypothesis is that following quinolone treatment, mutations conferring resistance occur additively, beginning with mutations in the topoisomerases and ultimately including overproduction of AcrAB and that the most resistant isolates contain additional mutations, including another multidrug efflux pump. Preliminary data support these hypotheses. Overproduction of any multidrug efflux pump has far reaching therapeutic consequences; antimicrobial agents from multiple different categories, in addition to the quinolones, would be ineffective against these bacteria. With the combined basic, clinical, statistical, genomic, and bioinformatic expertise of the investigators and the size of our patient population, we are uniquely poised to carry out the following specific aims: (1) Identify and categorize genetic alterations that cause quinolone resistance in clinical isolates. We will use high through-put methods to detect mutations in the genes that encode quinolone resistance. Statistical methods will be used to analyze potential interrelationships between the mutations. (2) Perform a prospective analysis of patient data. We will: (a) use the high-throughput methods developed in specific aim 1 to determine the genetic alterations occurring in E. coli isolated from patients hospitalized in the Texas Medical Center compared to isolates from various consortia around the world; (b) perform genome typing; (c) analyze these data with respect to demographic and clinical data for the patients to determine the probable causes of quinolone resistance. Until we have a better understanding of the mechanisms used by bacteria to cope with drug pressure, we cannot design better inhibitors or control antimicrobial resistant infections.

性状（由申请人提供）：喹诺酮类是最常用的广谱抗菌剂。对这些药物的耐药性已成为一个严重的公共卫生问题。导致耐药性的药物靶点拓扑异构酶突变已有充分的文献记载。此外，多药外排泵AcrAB的过量产生已被报道导致临床分离的大肠埃希菌对喹诺酮类药物耐药。杆菌 我们的长期目标是确定细菌对喹诺酮类药物的反应，并利用这些知识设计更有效的治疗方法。本研究的目的是鉴定导致临床大肠埃希菌喹诺酮类耐药的基因变异。大肠杆菌菌株，并确定喹诺酮耐药水平和频率，突变和其他患者协变量之间的相互关系。中心假设是，喹诺酮类药物治疗后，增加耐药的突变发生，从拓扑异构酶突变开始，最终包括AcrAB的过度产生，最耐药的分离株含有其他突变，包括另一种多药外排泵。初步数据支持这些假设。任何多药外排泵的过度生产都具有深远的治疗后果;除了喹诺酮类之外，来自多种不同类别的抗菌剂对这些细菌无效。 凭借研究者的基础、临床、统计、基因组和生物信息学专业知识以及我们患者人群的规模，我们有能力实现以下具体目标： (1)鉴定和分类临床分离株中引起喹诺酮耐药的遗传变异。我们将使用高通量的方法来检测编码喹诺酮耐药的基因突变。将使用统计方法分析突变之间的潜在相互关系。 (2)对患者数据进行前瞻性分析。我们将：（a）使用特定目标1中开发的高通量方法来确定E.将从德克萨斯州医学中心住院患者中分离的大肠杆菌与来自世界各地各种财团的分离株进行比较;（B）进行基因组分型;（C）根据患者的人口统计学和临床数据分析这些数据，以确定可能的原因。喹诺酮耐药性。在我们更好地了解细菌科普药物压力的机制之前，我们无法设计更好的抑制剂或控制抗生素耐药性感染。